Steve Worland. eFFECTOR

Eye­ing the 'trans­latome,' Pfiz­er ties an­oth­er knot with biotech part­ner for pre­clin­i­cal, next-gen tar­get­ed ther­a­pies

Af­ter close­ly fol­low­ing eF­FEC­TOR Ther­a­peu­tics’ work on next-gen tar­get­ed can­cer ther­a­pies in the past two years, chip­ping in its own ven­ture dol­lars and ink­ing an I/O com­bo col­lab­o­ra­tion with its PD-L1, Pfiz­er is bet­ting on a sec­ond drug can­di­date from the biotech part­ner.

The pre­clin­i­cal deal starts rel­a­tive­ly small — $15 mil­lion up­front — but Pfiz­er has com­mit­ted to $492 mil­lion in R&D fund­ing and mile­stones, as well as roy­al­ties and an op­tion to co-pro­mote in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.